1. IRMD announces a special cash dividend of $0.50 per share. 2. The dividend is payable on December 30, 2025, to recorded stockholders. 3. IRMD reports 17 consecutive quarters of record revenue growth. 4. Company plans future investments including a next-generation IV pump commercialization. 5. Strong cash balance exceeds operational needs, indicating financial health.
FAQ
Why Bullish?
The special dividend reflects strong financial health and stable revenue growth. Historical examples show dividends typically boost stock prices; e.g., recent quarterly dividends from other companies have had positive impacts on market perception.
How important is it?
The dividend announcement signifies financial strength, likely attracting new investors and boosting stock price due to perceived long-term profitability.
Why Short Term?
The immediate payout of the dividend may enhance investor sentiment quickly. Companies that announce dividends often see a short-term boost as investors buy in.
iRadimed Corporation Declares Special Cash Dividend of $0.50 per Share
ORLANDO, Fla., Dec. 08, 2025 (GLOBE NEWSWIRE) — iRadimed Corporation (NASDAQ: IRMD), a leader in MRI-compatible medical devices, has announced the approval of a special cash dividend of $0.50 per share for its outstanding common stock. This dividend will be payable on December 30, 2025, to stockholders of record as of the close of business on December 17, 2025.
Financial Highlights and Strategic Rationale
The Board of Directors made this decision based on the company’s strong financial performance. iRadimed has reported 17 consecutive quarters of record revenue and has maintained a robust operational cash flow. As of the end of Q3 2025, the company reported a cash and cash equivalents balance of $56.5 million, providing ample liquidity for normal operations, including the transition to a new manufacturing facility and future investments.
Roger Susi, Chairman, President, and CEO of iRadimed, stated, “One of the Board’s commitments is maximizing returns to our stockholders. Given our excess cash, we believe that returning it in the form of this special cash dividend is the best course of action.”
Future Dividend Prospects and Conditions
It’s important to note that any future dividends, whether regular or special, will be determined at the discretion of the Board. Several factors will influence this decision, including:
- Company financial condition
- Earnings and capital requirements
- Cash flow and liquidity needs
- General business conditions
- Growth opportunities
There are no guarantees regarding the continuation of regular dividends or any declarations of special dividends after this payment.
About iRadimed Corporation
iRadimed Corporation specializes in the design, manufacturing, marketing, and distribution of innovative MRI-compatible medical devices. The company is notably the first and only provider of a non-magnetic IV infusion pump system that operates safely around MRI environments. This infusion system minimizes complications typically associated with MRI procedures.
The company’s patented MRidium® MRI-compatible IV infusion pump features a non-magnetic ultrasonic motor and safely delivers critical medications during MRI scans. Additionally, the iRadimed 3880 patient vital signs monitoring system is designed for use in high-magnetic environments, ensuring accurate and continuous monitoring of patients’ vital signs.
Forward-Looking Statements
This announcement may contain “forward-looking statements” under the Private Securities Litigation Reform Act of 1995. These statements relate to anticipated future events and trends affecting the company’s operations and results, including the potential for future dividends and the commercialization of new medical devices.
Shareholders and potential investors are urged to consider the inherent risks associated with such forward-looking statements, which may cause actual results to differ from projections. For a detailed understanding, these risks are discussed in the company's filings with the U.S. Securities and Exchange Commission.
Contact Information
For further inquiries, please contact the Investor Relations department of iRadimed Corporation:
Phone: (407) 677-8022